Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHM-029 in Relapsed or Refractory Acute Myeloid Leukemia
NCT07751991Phase 1Recruiting
- Sponsor
- CHARM Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
Phase 1, open-label trial of CHM-029 in acute myeloid leukemia (AML) (2 arms), sponsored by CHARM Therapeutics. Primary endpoints: Dose Limiting Toxicities at Day 28, Adverse Events at 3 years and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
CHM-029
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07751991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751991.